CVRx, Inc. (CVRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.05+1.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CVRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 5.0% |
Growth built into the price is above our model estimate.
The price assumes 68.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CVRX — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, CVRx, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange…
Why it matters: A CFO change can affect financial strategy and investor confidence. It’s important to see how this unfolds.
Worry ifCVRx has a new CFO. This person has helped stabilize the company's finances.
Less concerning ifThere are more problems after the CFO change.
Why it matters: A permanent sales leader can stabilize the sales team and improve revenue growth.
Supportive ifA new Chief Revenue Officer was announced. They have a strong record in medical device sales.
Worry ifThe company has had interim leadership for over three months. No permanent appointment has been made.
Why it matters: Keeping the revenue guidance shows the company is on track for growth. It helps build investor confidence.
Supportive ifCVRx confirms revenue guidance for 2026 remains between $63 million and $67 million.
Worry ifCVRx lowers its revenue guidance below $63 million.
Why it matters: A new CFO can change financial plans and boost investor trust.
Watch forAnnouncement of a new CFO who has relevant experience.
Also watch forContinued delay in appointing a new CFO.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$267 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $853 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,808 loss on $10,000 · 78.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Filling this role fast could help sales leadership during a key time.
Supportive ifAnnouncement of a permanent Chief Revenue Officer within the next three months.
Worry ifNo announcement of a new Chief Revenue Officer in the next three months.
Why it matters: Maintaining or revising revenue guidance shows the company's growth outlook. A change could impact investor confidence.
Supportive ifRevenue guidance for 2026 remains between $63 million and $67 million.
Worry ifRevenue guidance is now below $63 million.
Why it matters: Meeting or beating guidance shows strong demand. It also shows good sales execution.
Supportive ifQ3 revenue reported at or above $13.5 million.
Worry ifQ3 revenue was below $13.5 million. This shows ongoing sales challenges.
Why it matters: Meeting or exceeding this revenue target shows strong growth momentum for CVRx.
Supportive ifQ2 revenue reported at $15.1 million or higher.
Worry ifQ2 revenue reported below $15.1 million.
Why it matters: Keeping this margin shows good cost control and strong pricing.
Supportive ifQ3 gross margin reported at or above 86%.
Worry ifQ3 gross margin reported below 86%.
Why it matters: Controlling expenses is key for better financial health. It helps reduce losses.
Worry ifOperating costs were between $99 million and $101 million.
Less concerning ifOperating expenses went over $101 million. This shows poor cost control.
Why it matters: A new CFO can change financial plans and operations. Watch for any bad effects.
Worry ifFinancial results do not drop much after the CFO change.
Less concerning ifFinancial results get worse after the CFO leaves.
Why it matters: A rise in gross margin guidance means better profits. This may help how investors feel.
Supportive ifCVRx raises gross margin guidance to between 85% and 87%.
Worry ifCVRx lowers gross margin guidance below 85%.
Why it matters: U.S. revenue growth indicates the effectiveness of CVRx's market expansion efforts. Strong growth supports confidence in the business.
Supportive ifU.S. revenue for Q3 2026 exceeds $14.5 million, reflecting continued growth.
Worry ifU.S. revenue for Q3 2026 is below $13.5 million, indicating potential issues in market execution.
Why it matters: Good trial results could greatly increase the number of patients for Barostim. This would help growth.
Supportive ifLook for news about more patients joining the BENEFIT-HF trial or positive early results.
Worry ifDelays in patient enrollment or negative results from the trial.
Why it matters: Keeping costs low is key for better finances and making money.
Supportive ifOperating expenses for Q3 2026 stay within the range of $99 million to $101 million.
Worry ifIf operating costs exceed $101 million, it shows poor cost control.
Why it matters: The change in sales leadership could affect sales during an important growth time.
Watch forSales go up under Paul Verrastro's short-term leadership. This leads to more revenue.
Also watch forSales drop or stay the same, showing the leadership change is not working.